-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer is the first malignant tumor threatening women's health.
Triple-negative breast cancer (TNBC) accounts for about 15%-20% of all breast cancers.
Compared with other breast cancer subtypes, TNBC has the best clinical prognosis.
Poor, prone to distant metastasis, and high risk of recurrence
.
However, at this stage, chemotherapy, radiotherapy and immunotherapy , which have been widely used in the clinical treatment of breast cancer, still have certain limitations
.
breast cancer immunity
On February 22, 2022, Lu Lei's team from Fudan University School of Basic Medicine, Xu Yanping's team from Tongji University and Zhang Song's team from Nankai University jointly published a paper on PNAS entitled D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of Research results of PD-L1
.
This study revealed that D-mannose can promote its degradation by affecting the glycosylation of PD-L1, thereby improving the efficacy of TNBC immunotherapy and radiotherapy
.
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1 D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
Mannose, an isomer of glucose, enters cells through glucose transporters
.
Mannose is catalyzed by hexokinase to generate 6-phosphate-mannose (M6P) in cells, M6P can be catalyzed by phosphomannose isomerase (PMI) into the glycolytic pathway or by phosphomannose mutase (PMM2) Catalyzes entry into the glycosylation pathway
.
Nature Nature
Inspired by this work, Lu Lei's team attempted to explore whether various hexose sugars have an effect on tumor immunity
.
Through screening, the researchers found that high concentrations of D-mannose could degrade the PD-L1 protein in TNBC cells
.
Tumor Immunity Molecular Cell Molecular Cell
In conclusion, this study revealed a new function of D-mannose—degrading PD-L1 protein, reported for the first time the promoting effect of D-mannose on TNBC immunotherapy and radiotherapy, and provided a new strategy for the clinical treatment of TNBC
.
.
This study revealed a new function of D-mannose—degrading PD-L1 protein, and reported for the first time the promotion of D-mannose on TNBC immunotherapy and radiotherapy, providing a new strategy for the clinical treatment of TNBC
.
Author information: Zhang Ruonan, a 2020 doctoral student at the School of Basic Medicine of Fudan University, is the first author of this article
.
author information:
Original link: https:// Leave a comment here